帕罗西汀对老年食管癌根治术后患者的抑郁情绪和免疫功能的影响

Effect of paroxetine on depression and immune function in elderly patients with esophageal cancer after radical resection

目的研究帕罗西汀对老年食管癌患者行根治术后的抑郁情绪及免疫功能的影响。方法将2015年1月~2019年1月期间在我院治疗的100例伴有抑郁的行根治术的老年食管癌患者随机分为两组,50例对照组术后接受常规治疗并辅以心理指导,观察组50例在对照组基础上口服帕罗西汀片进行治疗。对比两组患者在治疗前后的焦虑自评量表(SAS)和抑郁自评量表(SDS)评分情况,并对比其治疗前后的免疫功能水平IgG(免疫球蛋白G)、IgM(免疫球蛋白M)、CD3+(分化簇3)、CD4+(分化簇4)、CD8+(分化抗原CD8)、NK细胞(自然杀伤细胞)、CD4^+/CD8^+比值等。结果治疗前,两组患者组间的SAS和SDS评分无显著差异(P>0.05),治疗后,两组患者的抑郁和焦虑情况均得到了改善,且观察组的改善效果较对照组更佳(P<0.05);两组患者治疗前的IgG、IgM、CD3+、CD4+、CD8+、NK细胞比例以及CD4^+/CD8^+比值的情况无明显差异(P>0.05),治疗后观察组患者的CD3^+、CD4^+、CD8^+、NK细胞比例以及CD4^+/CD8^+比值的改善情况显著优于对照组患者(P<0.05)。结论帕罗西汀可以改善行食管癌根治术的老年患者的抑郁情绪,并能提高其免疫功能。

Objective To study the effects of paroxetine on depression and immune function in elderly patients with esophageal cancer after radical resection. Methods 100 elderly patients with esophageal cancer after radical resection were selected and divided into two groups,50 case in each group. The control group received conventional postoperative treatment supplemented by psychological guidance,and the observation group received oral paroxetine hydrochloride tablets for treatment on the basis of the control group. The SAS scores,SDS scores,and the level of IgG,IgM,CD3 + 3 clusters(differentiation),CD4 + 4 clusters(differentiation),CD8 + CD8 antigen(differentiation),NK cells(natural killer cells)and the ratio of CD4 +/CD8 + were compared between two groups. Results Before treatment,there were no significant difference in SAS scores,SDS scores,IgG,IgM,CD3+,CD4+,CD8+,NK cell ratio and CD4+/CD8+ ratio between two groups. After treatment,the depression and anxiety of the patients in both of two groups had been effectively improved,and the observation group was better than control group(P< 0.05);The improvement of CD3+,CD4+,CD8+,NK cell ratio and CD4+/CD8+ ratio in the observation group was significantly better than that in the control group(P<0.05). Conclusion The paroxetine can improve the depression and immune function in elderly patients with esophageal cancer after radical resection.